Raymond James & Associates’s Axonics, Inc. Common Stock AXNX Stock Holding History

Raymond James & Associates’s Portfolio AXNX Stock Details AXNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-8,540	Closed	-$431K	–	3961
2023 Q2	$431K	Sell	8,540 -2,788	-25%	-$148K	﹤0.01%	3029
2023 Q1	$618K	Sell	11,328 -7,458	-40%	-$436K	﹤0.01%	2787
2022 Q4	$1.17M	Buy	18,786 +8,274	+79%	+$549K	﹤0.01%	2335
2022 Q3	$740K	Buy	10,512 +6,843	+187%	+$472K	﹤0.01%	2582
2022 Q2	$208K	Buy	+3,669	New	+$201K	﹤0.01%	3490
2022 Q1	–	Sell	-5,757	Closed	-$322K	–	4305
2021 Q4	$322K	Buy	5,757 +927	+19%	+$56.6K	﹤0.01%	3394
2021 Q3	$314K	Sell	4,830 -2,764	-36%	-$189K	﹤0.01%	3376
2021 Q2	$482K	Buy	+7,594	New	+$448K	﹤0.01%	3097
2020 Q1	–	Sell	-8,778	Closed	-$243K	–	3758
2019 Q4	$243K	Buy	+8,778	New	+$210K	﹤0.01%	3225

Other funds holding AXNX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

CIP

Champlain Investment Partners Burlington, Vermont $3.89B AUM 16.15% 1-Year Est. Return

BAMCO Inc New York $66.6B AUM 7.35% 1-Year Est. Return

Axa Paris, France $91.9M AUM 27.41% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Hood River Capital Management Palm Beach Gardens, Florida $13.8B AUM 163.97% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Raymond James & Associates's AXNX Position: Q3 2023 in Review

Raymond James & Associates sold out of Axonics, Inc. Common Stock (AXNX) in Q3 2023, closing a stake of 8,540 shares — an estimated $431K sold.

Raymond James & Associates first reported a position in AXNX in Q4 2019 and held it in 9 quarters. The position peaked at $1.17M in Q4 2022. 220 funds tracked by Wall St. Rank hold AXNX as of Q3 2023.

Raymond James & Associates reported no remaining Axonics, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
Raymond James & Associates sold 8,540 Axonics, Inc. Common Stock shares in Q3 2023, an estimated $431K.
Raymond James & Associates first reported a position in Axonics, Inc. Common Stock in Q4 2019 and held it in 9 quarters.
Raymond James & Associates's Axonics, Inc. Common Stock position peaked at $1.17M in Q4 2022.
220 funds tracked by Wall St. Rank held Axonics, Inc. Common Stock as of Q3 2023.

Based on Raymond James & Associates's 13F filing for Q3 2023, filed 24 Oct 2023.